Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1/2 1

Status

Recruiting 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Breast Neoplasms 1316Neoplasms 1104Carcinoma, Non-Small-Cell Lung 916Prostatic Neoplasms 747Colorectal Neoplasms 645Lung Neoplasms 621Neoplasm Metastasis 470Multiple Myeloma 444Leukemia, Myeloid, Acute 440Pancreatic Neoplasms 392Ovarian Neoplasms 388Melanoma 346Carcinoma, Hepatocellular 308Brain Neoplasms 290Squamous Cell Carcinoma of Head and Neck 285Recurrence 285Glioblastoma 260Stomach Neoplasms 252Head and Neck Neoplasms 250Precursor Cell Lymphoblastic Leukemia-Lymphoma 238Carcinoma, Renal Cell 237Lymphoma 235Triple Negative Breast Neoplasms 233Endometrial Neoplasms 221Uterine Cervical Neoplasms 217Hematologic Neoplasms 216Urinary Bladder Neoplasms 212Lymphoma, Non-Hodgkin 203Glioma 202Sarcoma 200

Interventions

Taxes 1Standard of Care 1Panitumumab 1Pancreaticoduodenectomy 1Optical Imaging 1Losartan 1Gemcitabine 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Pancreatic Adenocarcinoma × 90 days × Clear all
NCT07619391 2026-06-02

MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer

Ohio State University Comprehensive Cancer Center

Phase NA Recruiting
30 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT07547033 2026-04-23

EQUINOXE

Assistance Publique - Hôpitaux de Paris

Phase NA Not yet recruiting
150 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT05973331 2026-04-22

Prospective Validation of an EHR-based Pancreatic Cancer Risk Model

Beth Israel Deaconess Medical Center

Active not recruiting
6,134,060 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT05077800 2026-04-13

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Active not recruiting
70 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT05624918 2026-04-08

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Big Ten Cancer Research Consortium

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT03384238 2026-03-17

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Stanford University

Phase 1/2 Recruiting
27 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡